![](/content/dam/global/hcpportal/master/images/homepage/products/incruse/2017/Incruse-Bar-Arial-Font.png)
Adapted from Feldman et al. 2016 1
FEV1, forced expiratory volume in 1 second.
![](/content/dam/global/hcpportal/master/images/homepage/products/incruse/2017/Incruse-line-Efficacy-2.png)
Adapted from Feldman et al. 2016 1
FEV1, forced expiratory volume in 1 second.
![](/content/dam/global/hcpportal/master/images/homepage/products/incruse/2017/Line-7a3.png)
Adapted from Rheault et al. 2016 2
CI, confidence interval; FEV1, forced expiratory volume in 1 second.
![](/content/dam/global/hcpportal/master/images/homepage/products/incruse/2017/Incruse-SGRQ-V2.png)
Adapted from Donohue et al. 2013
SGRQ, St George’s Respiratory Questionnaire.
![](/content/dam/global/hcpportal/master/images/homepage/products/incruse/2017/Incruse-TDI-Use-this.png)
Adapted from Donohue et al. 2013 4
TDI, Transition Dyspnoea Index
References:
- Feldman G et al. Int J Chron Obstruct Pulmon Dis 2016; 11:719–730.
- Feldman G et al. Int J Chron Obstruct Pulmon Dis 2016; 11:719–730 (supplementary material).
- Rheault T et al. ERJ Open Res 2016;2: pii:00101-2015.
- Ismaila AS et al. Int J Chron Obstruct Pulmon Dis 2015; 10:2495–2517.
- Donohue JF et al. Respir Med 2013; 107:1538–1546.
INCRUSE™ ™ y ELLIPTA™ Instructivo son marcas registradas del grupo de compañías GlaxoSmithKline